13F Holdings
中文EN

AHG Akso Health Group Annual reports only

Services-Business Services, NEC · Nasdaq · SEC CIK 1702318 · Fiscal year ends 03/31

Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-6.4%
TTM net income YoY86.2%
TTM EPS YoY-93.8%
Revenue 3-yr CAGR1.6%
Net income 3-yr CAGR—

Margins

Gross margin-0.1%
Operating margin-149.7%
Net margin-135.0%
FCF margin-92.5%
EBITDA margin-132.5%

Returns

ROE-9.8%
ROA-9.2%
ROIC (approx.)-16.1%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets4.6%
Debt / equity0.00x
Current ratio21.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.69x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$13.83M$14.78M$2.41M$13.18M$6.00M
Cost of revenue$13.84M$15.06M$2.29M$11.91M$5.39M
Gross profit-$11,315-$281,526$122,132$1.27M$605,134
R&D expense————$421,186
SG&A expense$3.99M$3.64M$8.59M$15.53M$2.67M
Operating income-$20.70M-$166.30M-$8.64M-$14.27M-$3.26M
Interest expense————$804,138
Pretax income-$20.70M-$166.27M-$9.09M-$13.07M-$4.01M
Income tax-$1.99M-$30.80M$24,988$17,549$92,816
Net income-$18.67M-$134.98M-$9.46M-$1.36M-$16.85M
EBITDA-$18.33M-$164.15M——-$3.24M
EPS (basic)0.010.160.07-0.02-0.28
EPS (diluted)0.010.160.07-0.02-0.28
Weighted avg. shares (diluted)2.17B855.29M141.52M68.60M59.61M
Banking
Provision for credit losses————$5.56M
Balance sheet
Cash & equivalents$170,572$176.23M$85.17M$9.19M$21.93M
Receivables$1.28M$954,200—$7.70M—
Inventory$200,135$190,242$191,201$1.69M$7.80M
Current assets$189.55M$196.12M$142.02M$20.46M$62.81M
PP&E, net$12,015$16,148——$55,433
Goodwill—$10.83M———
Intangibles$58,319$7.88M———
Total assets$189.63M$214.95M$142.02M$20.46M$62.81M
Current liabilities$8.71M$13.81M$3.59M$11.62M$50.52M
Total liabilities$8.71M$15.80M$3.59M$11.62M$50.52M
Shareholders' equity$180.93M$199.12M$138.37M$8.73M$12.28M
Shares outstanding—1.66B437.17M68.60M68.60M
Cash flow statement
Operating cash flow-$12.79M$1.18M$1.35M-$3.25M-$8.63M
Capital expenditure$1,638$154,460——$4,861
Free cash flow-$12.79M$1.02M——-$8.63M
Investing cash flow-$163.46M-$105.91M-$54.72M$18.47M-$19.96M
Financing cash flow$350,000$195.88M$131.65M-$27.51M$34.78M
Depreciation & amortization$2.37M$2.15M——$18,390
Stock-based compensation————$391,625

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.